research
A Diet Signal Appears Strongest Where Biomarkers Were Highest
A secondary MIND trial analysis suggests baseline amyloid and tau markers may modify cognitive response.
Summary
A secondary MIND trial analysis suggests baseline amyloid and tau markers may modify cognitive response.
Rush researchers reanalyzed data from the three-year MIND diet trial and found that cognitive response varied with baseline blood levels of amyloid beta 40 and phosphorylated tau 181. Participants with higher markers appeared more likely to benefit from the dietary intervention. The original trial did not find a statistically significant overall cognitive advantage over its control diet, and this post hoc analysis was designed to find patterns rather than confirm a prespecified treatment effect.
Why it matters
A secondary MIND trial analysis suggests baseline amyloid and tau markers may modify cognitive response.
Limits and context
- The original trial did not find a statistically significant overall cognitive advantage over its control diet, and this post hoc analysis was designed to find patterns rather than confirm a prespecified treatment effect.
Key claims
A secondary MIND trial analysis suggests baseline amyloid and tau markers may modify cognitive response.
Qualification: The original trial did not find a statistically significant overall cognitive advantage over its control diet, and this post hoc analysis was designed to find patterns rather than confirm a prespecified treatment effect.
Evidence: source-2026-07-21-007
Sources
- Rush via Newswise: MIND diet biomarker responseRush via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.